Medtech vs digital health fundraising in 2026

Medtech vs digital health fundraising splits on two different equations. Digital health seeds run on SaaS math, ARR, NRR, CAC payback, and close in 8 to 12 weeks with generalist software VCs. Medtech seeds run on milestone math, 510(k) path, FDA class, clinical evidence, and take 6 to 9 months with specialist device investors. The decks look nothing alike.

Most founders building in healthcare pitch the wrong investor first and spend three months learning why. If you're building a medical device, a general software VC will ghost you after diligence hits the regulatory section. If you're building a SaaS product for clinicians, a medtech specialist will pass because your ARR chart is the whole pitch and they don't underwrite SaaS. Medtech vs digital health fundraising is not one category with two flavors, it's two separate capital markets that happen to share the word "health."

The sector is growing on both sides. Digital health funding hit $3.7 billion in Q1 2024, up 48% quarter over quarter, per CB Insights State of Digital Health Q1'24. Medtech stayed steady at $3.3 billion in Q2 2024 and $3.2 billion in Q3 2024, per PitchBook's quarterly medtech reports. Similar dollar volumes, completely different check dynamics underneath.

The SaaS math vs milestone math split

Digital health VCs underwrite software. Medtech VCs underwrite regulatory risk. That is the entire difference, and every downstream difference, in deck structure, timeline, valuation, and investor list, flows from it.

If you're a healthcare SaaS seed, your seed deck is 80% SaaS metrics and 20% healthcare-specific context. ARR trajectory, net revenue retention, logo churn, CAC payback in months, sales cycle length, pilot-to-paid conversion. The healthcare layer is HIPAA compliance, integration with Epic or Cerner, reimbursement pathway if applicable, and one slide on clinical validation. A digital health seed VC like BoxGroup or General Catalyst will spend 90% of diligence on the software business and 10% on the clinical angle.

If you're a medical device seed or diagnostic, your seed deck is 60% regulatory and clinical, 40% commercial. The questions are different: what's your FDA class, is this a 510(k) or De Novo or PMA, what's your predicate device, what's the pre-submission feedback from FDA, who's on your clinical advisory board, what animal or human data do you have, what's the reimbursement CPT code path. A medtech seed investor spends the majority of diligence on the regulatory strategy and IP position, and the revenue chart barely matters because there often isn't one yet.

How the deck differs, section by section

Build the deck around the investor's actual diligence checklist. Here's what each audience wants on each slide.

Do: write two versions of the deck if you have a hybrid product (device plus software). Send each audience the version that leads with their equation. Don't: try to make one deck work for both. A generalist will read a medtech deck as "too slow" and a device VC will read a SaaS deck as "not a real medical product."

Which funds actually write checks, and where

The fund list is where founders lose the most time. Some firms claim to do both and in practice only write one.

Pure digital health seed VCs (software diligence, SaaS metrics):

• BoxGroup, General Catalyst, Andreessen Horowitz Bio + Health, Define Ventures, Oak HC/FT on the later side. Andreessen Horowitz is the most active investor in top-tier digital health startups, backing 8 companies in the 2024 Digital Health 50 cohort.
• What they fund: provider workflow, payer ops, patient engagement, AI scribing, virtual care, healthcare SaaS with clear ARR.
• What they skip: anything that needs a 510(k). If you have to file with FDA for a hardware product, you're on the wrong list.

Pure medtech seed investors (regulatory diligence, milestone math):

• Venrock, 5AM Ventures, Lightstone Ventures, KdT Ventures, Action Potential Capital, Sante Ventures, RA Capital, plus strategic venture arms like J&J JJDC and Medtronic Ventures.
• What they fund: cardiovascular devices, surgical robotics, diagnostics, implantables, point-of-care instruments. Medtech investment is heavily concentrated in cardiovascular ($539.4M in Q2 2024) and diagnostics ($403.2M).
• What they skip: pure software plays, even if clinician-facing. If there's no FDA filing, the thesis doesn't fit.

The crossover list (will do both but with different process and different partners):

• Andreessen Horowitz Bio + Health, General Catalyst, Khosla Ventures, GV, NVentures. These firms have internal splits. Getting routed to the wrong partner inside a crossover fund is worse than pitching a specialist, because the wrong partner will pass and the fund goes on your "passed" list forever.
• Tactical move: research the partner, not the fund. Look at their last 5 personal investments. If they led a medical device deal in the last 12 months, they're a device partner. If all five were SaaS, don't pitch them your device.

Timeline reality: 12 weeks vs 6-9 months

Digital health seeds close in 8 to 12 weeks if the metrics support it. First meeting to term sheet commonly runs 4 to 6 weeks, then another 3 to 5 weeks to close. That matches the software venture cadence across the rest of the portfolio.

Medtech seeds run 6 to 9 months from first meeting to wire. Regulatory and clinical diligence cannot be compressed. Funds will want to talk to FDA regulatory consultants, pull freedom-to-operate opinions, talk to 3 to 5 KOL physicians, and in some cases wait for a pre-submission meeting outcome. A seed round that needs to land in three months is a digital health round. A seed round that can take a year and needs to land next to a specific regulatory milestone is a medtech round.

Plan the runway accordingly. A medtech founder who starts raising 4 months before zero cash is already late. A digital health founder with 4 months of runway is on the aggressive side of normal.

Don't: announce a medtech seed raise with a hard 60-day close timeline. Specialist funds will read it as inexperience. Do: tie the raise to a regulatory milestone on the ask slide, so the use of funds tells the VC exactly what money buys.

Valuation and check size patterns

Digital health seeds in 2026 are landing at software-comparable valuations when the SaaS metrics justify it: $10-20M post on $2-5M raised is common for a pre-revenue or <$500K ARR company. The average digital health deal size grew 38% in early 2024, and the rebound is increasingly driven by mega-rounds of $100M+ at later stages, which pulls seed valuations up.

Medtech seeds are usually bigger and priced off milestones, not ARR. A $5-10M seed on a $20-30M post is typical because the capital is buying a specific regulatory or clinical deliverable, and running out of cash before that deliverable is worth nothing. Bridges are common and expected. If you raise $3M when you needed $7M to hit 510(k) submission, specialist investors will not write the bridge on favorable terms.

What to stop doing

• Don't send a 40-slide medtech deck to a SaaS generalist. They'll skim slide 3, see "FDA", and mark it low priority.
• Don't benchmark your medtech seed against TechCrunch headlines about digital health mega-rounds. Different market, different math.
• Don't claim both are "the same thing, healthcare." Every investor you say that to will downgrade you silently.
• Don't hire a SaaS-only seed advisor if you're building a device. The intro list will be wrong.

If you're running outreach across both types of funds at once (say, a hybrid product with a software arm and a device arm), tools like Causo can segment the list by partner-level investment history so the device partner gets the device pitch and the SaaS partner gets the SaaS pitch.

FAQ

Are digital health VCs different from medtech VCs?

Mostly yes. Digital health seeds are funded by generalist software firms like a16z, BoxGroup, and General Catalyst who underwrite on SaaS metrics. Medtech seeds are funded by specialist device investors who underwrite on regulatory path and clinical evidence. A small overlap exists at large multi-stage funds with healthcare arms.

Do medtech seeds take longer?

Yes, materially. Digital health seeds typically close in 8-12 weeks off software diligence. Medtech seeds run 6-9 months because diligence includes regulatory strategy, pre-submission FDA feedback, freedom-to-operate IP review, and clinical advisor calls. Plan the raise around that calendar.

What's easier to raise, digital health or medtech?

Digital health is faster to capitalize but more competitive on metrics. Medtech is slower and needs a credible 510(k) or De Novo path, but the diligence bar on revenue is lower at seed. Pick the format that fits your actual product, not the one that seems easier.